AXIM sets up hemp-based oral care division

AXIM Biotechnologies, Inc. (OTC:AXIM) has launched a hemp-based Oral Care Division. In line with this strategy, the industry-leading commercial hemp biotechnology company has filed a provisional patent relating to the unique formulation of its cannabinoid-containing oral care products. 

 

These new patent-pending formulations for toothpaste, dentifrice, and oral rinse liquid will target the daily use market as well as remedies for use in resolution of oral care infections and gum diseases.

 

AXIM chief executive officer George E. Anastassov, MD, DDS, MBA, said he expects Oral care to be an industry-leading division where research and development will be focused on commercial hemp-derived cannabinoids for oral health. 

 

“We know that certain cannabinoids act as effective anti-inflammatory, bactericidal, anti-proliferative, and regenerating agents. We also know that the oral cavity, being continuously traumatized by chewing, speaking, and being populated with numerous infectious organisms, is in need of oral health products,” Dr. Anastassov said.

 

Through unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. CBD, CBG, CBN, among others), AXIM is focused upon finding solutions for conditions for which there is currently no effective treatment. The company’s initiatives encompass the complete use of the industrial hemp plant leaving a net negative carbon footprint on the environment.